Overnight in the US, there were a few analyst’s reports...

Overnight in the US, there were a few analyst’s reports published on Anteris Technologies with bullish ratings.

Barclays:
Barclays analyst Matt Miksic initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $22 price target The timing for the company’s entry into transcatheter aortic valve replacement “could not look better,” the analyst tells investors in a research note. The firm says the market is now “deeply entrenched” between the preference for balloon-expandable valve and the need for hemodynamics in smaller valves. It believes Anteris ‘ DurAVR can provide balloon-expandable valve delivery for all valve sizes, and meet the growing demand for valve replacement.

TD Cowen:
TD Cowen analyst Joshua Jennings initiated coverage of Anteris Technologies (AVR) with a Buy rating and $15 price target Anteris has developed DurAVR, a first-in-class biomimetic transcatheter aortic valve replacement platform that has “disruptive potential,” the analyst tells investors in a research note. The firm says the hemodynamic outcomes generated in the clinical development program are differentiated and could drive Anteris to capture meaningful share in the $10B TAVR market in replicated in the next trial.

Cantor Fitzgerald:
Cantor Fitzgerald analyst Ross Osborn initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $9 price target Anteris is a clinical-stage structural heart company discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosi, the analyst tells investors in a research note. Cantor holds a favorable view of the estimated $7.1B transcatheter aortic valve replacement aortic stenosis and valve-in-valve markets and believes Anteris’s DurAVR technology is differentiated from competitors and should serve to drive fast adoption.

Currently, the analyst consensus on Anteris Technologies Global Corp. is a Strong Buy with an average price target of $15.33, which is a 173.26% upside from current levels. In a report released today, Barclays also initiated coverage with a Buy rating on the stock with a $22.00 price target.

Not advice, DYOR